ES2062206T3 - Composicion estabilizada de fgf y su produccion. - Google Patents

Composicion estabilizada de fgf y su produccion.

Info

Publication number
ES2062206T3
ES2062206T3 ES90112850T ES90112850T ES2062206T3 ES 2062206 T3 ES2062206 T3 ES 2062206T3 ES 90112850 T ES90112850 T ES 90112850T ES 90112850 T ES90112850 T ES 90112850T ES 2062206 T3 ES2062206 T3 ES 2062206T3
Authority
ES
Spain
Prior art keywords
fgf protein
fgf
production
composition
stabilized
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90112850T
Other languages
English (en)
Inventor
Yohko Akiyama
Minoru Yoshioka
Nobuyuki Kitamori
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ES2062206T3 publication Critical patent/ES2062206T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fodder In General (AREA)

Abstract

SE DESCUBREN (1) UNA COMPOSICION DE PROTEINA FGF ESTABILIZADA LA CUAL COMPRENDE UNA PROTEINA FGF E HIDROXIPROPILO DE CELULOSA INSOLUBLE EN AGUA; (2) UN METODO PARA PREPARAR UNA COMPOSICION PROTEICA FGF ESTABILIZADA, EL CUAL COMPRENDE MEZCLAR UNA PROTEINA FGF CON HIDROXIPROPILO DE CELULOSA INSOLUBLE EN AGUA; Y (3) UN METODO PARA ESTABILIZAR UNA PROTEINA FGF, EL CUAL COMPRENDE MEZCLAR UNA PROTEINA FGF CON UN HIDROXIPROPILO DE CELULOSA INSOLUBLE EN AGUA, MEDIANTE LO CUAL SE PUEDE PROVEER UNA PROTEINA FGF ESTABILIZADA. LA COMPOSICION SE OBTIENE EN UN ESTADO SOLIDO EL CUAL ESTA PROVISTO DE ESTABILIDAD.
ES90112850T 1989-07-07 1990-07-05 Composicion estabilizada de fgf y su produccion. Expired - Lifetime ES2062206T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17622889 1989-07-07
JP13633390 1990-05-24

Publications (1)

Publication Number Publication Date
ES2062206T3 true ES2062206T3 (es) 1994-12-16

Family

ID=26469955

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90112850T Expired - Lifetime ES2062206T3 (es) 1989-07-07 1990-07-05 Composicion estabilizada de fgf y su produccion.

Country Status (14)

Country Link
US (1) US5189148A (es)
EP (1) EP0406856B1 (es)
JP (1) JP2536247B2 (es)
CN (1) CN1049106A (es)
AT (1) ATE102044T1 (es)
AU (1) AU632344B2 (es)
CA (1) CA2020654A1 (es)
DE (1) DE69006947T2 (es)
DK (1) DK0406856T3 (es)
ES (1) ES2062206T3 (es)
FI (1) FI903440A0 (es)
HU (1) HU205862B (es)
IE (1) IE902470A1 (es)
NO (1) NO902995L (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
US5500409A (en) * 1990-10-01 1996-03-19 Thomas Jefferson University Method for inhibiting collagen synthesis by keloid fibroblasts
TW209174B (es) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
ES2109362T3 (es) 1991-06-21 1998-01-16 Univ Cincinnati Unas proteinas administrables oralmente y metodo para hacerlas.
DE4121043A1 (de) * 1991-06-26 1993-01-07 Merck Patent Gmbh Knochenersatzmaterial mit fgf
CA2080537A1 (en) * 1991-10-21 1993-04-22 David B. Volkin Stabilized topical acidic fibroblast growth factor formulation
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5482929A (en) * 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DE4242889A1 (de) * 1992-12-18 1994-06-23 Merck Patent Gmbh Hohlendoprothesen mit Knochenwachstumsfördernder Füllung
JP3349535B2 (ja) * 1993-01-12 2002-11-25 フロイント産業株式会社 球形顆粒の製造方法
US5331095A (en) * 1993-04-12 1994-07-19 Scios Nova Inc. Process for purification of basic fibroblast growth factor
WO1994027630A1 (fr) * 1993-05-31 1994-12-08 Kaken Pharmaceutical Co., Ltd. Preparation de gel a base de gelatine reticulee contenant un facteur de croissance de fibroblaste de base
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
EP0943336A1 (en) * 1996-09-04 1999-09-22 Dott Research Laboratory Peptide-containing pharmaceutical compositions for oral administration
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US5851579A (en) * 1996-10-28 1998-12-22 Eastman Chemical Company Aqueous enteric coating compositions
EP1189523B1 (en) * 1999-06-07 2003-06-25 Fibersugar APS Particulate fibre composition
US20030228288A1 (en) 1999-10-15 2003-12-11 Scarborough Nelson L. Volume maintaining osteoinductive/osteoconductive compositions
MXPA02006324A (es) * 1999-12-23 2002-12-13 Pfizer Prod Inc Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US9387094B2 (en) 2000-07-19 2016-07-12 Warsaw Orthopedic, Inc. Osteoimplant and method of making same
US7323193B2 (en) 2001-12-14 2008-01-29 Osteotech, Inc. Method of making demineralized bone particles
EP1434608B1 (en) 2001-10-12 2018-08-22 Warsaw Orthopedic, Inc. Improved bone graft
FR2836011B1 (fr) * 2002-02-20 2004-05-14 Goemar Lab Sa Agent pour la stimulation des defenses naturelles des plantes et procede pour sa mise en oeuvre
CA2481214A1 (en) * 2002-04-01 2003-10-09 Kaken Pharmaceutical Co., Ltd. Viscous preparation for dental use containing basic fibroblast growth factor
AU2004247143B2 (en) 2003-06-11 2010-09-23 Warsaw Orthopedic, Inc. Osteoimplants and methods for their manufacture
WO2005058207A1 (en) 2003-12-11 2005-06-30 Isto Technologies, Inc. Particulate cartilage system
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
WO2007025290A2 (en) 2005-08-26 2007-03-01 Isto Technologies, Inc. Implants and methods for repair, replacement and treatment of joint disease
WO2007056671A1 (en) 2005-11-02 2007-05-18 Osteotech, Inc. Hemostatic bone graft
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US20090012629A1 (en) * 2007-04-12 2009-01-08 Isto Technologies, Inc. Compositions and methods for tissue repair
KR20110086045A (ko) 2008-10-24 2011-07-27 오스테오테크, 인코포레이티드 뼈 형성 촉진용 조성물 및 뼈 형성 촉진방법
EP2832848B1 (en) * 2012-03-30 2019-02-13 Ajinomoto Co., Inc. Culture medium for proliferating stem cell, which contains sulfated compound
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
US11746135B2 (en) 2015-11-27 2023-09-05 Masarykova Univerzita Thermostable FGF2 polypeptide, use thereof
JP2021138648A (ja) * 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor

Also Published As

Publication number Publication date
HU904116D0 (en) 1990-12-28
DE69006947T2 (de) 1994-08-25
AU632344B2 (en) 1992-12-24
DK0406856T3 (da) 1994-07-04
NO902995D0 (no) 1990-07-04
HU205862B (en) 1992-07-28
JP2536247B2 (ja) 1996-09-18
IE902470A1 (en) 1991-02-13
JPH04128239A (ja) 1992-04-28
NO902995L (no) 1991-01-08
HUT54895A (en) 1991-04-29
ATE102044T1 (de) 1994-03-15
CN1049106A (zh) 1991-02-13
EP0406856A2 (en) 1991-01-09
AU5879990A (en) 1991-01-10
CA2020654A1 (en) 1991-01-08
DE69006947D1 (de) 1994-04-07
FI903440A0 (fi) 1990-07-06
EP0406856A3 (en) 1991-04-10
EP0406856B1 (en) 1994-03-02
US5189148A (en) 1993-02-23

Similar Documents

Publication Publication Date Title
ES2062206T3 (es) Composicion estabilizada de fgf y su produccion.
DE69131589T2 (de) Ribosomen-inaktivierende Proteine, inaktive Vorläuferformen derselben, Verfahren zur Herstellung und eine Methode zur Nutzung
ATE82281T1 (de) Aryl-substituierte(n-piperidinyl)methyl und (npiperazinyl)methylazole mit antipsychotischer wirkung.
ATE232237T1 (de) Herstellung von funktionellen, menschlichen urokinaseproteinen
DE69003253T2 (de) Enzymhaltige zubereitung und eine solche zubereitung enthaltendes detergens.
YU45719B (sh) Postopek za pripravo mešano substituiranih enantiomerno čistih 1,2-diacil-sn-gli cero-3-fosfoholinov in 1,2-di-acil-sn-glicero-3-fosfoetanolaminov
NO922953L (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
DE3764724D1 (de) 2-phenylbenzoxepin-derivat.
DE58908857D1 (de) Verfahren zur Herstellung von 2,6-Dichlordiphenylaminessigsäurederivaten.
DE3852577D1 (de) Verfahren zur Herstellung von Dodecahydro-3a,6,6,9a-tetramethylnaphtho[2,1b]furan und von Haloethyldecalin-Derivaten.
AU591305B2 (en) Improved process for preparing 5,6-substitued-2,4- quinazolinediamines and novel intermediates
DE3481430D1 (de) 2-oxocarbonsaeurereduktase, ihre herstellung und verwendung.
DE3887212D1 (de) Verfahren zur Herstellung von Derivaten von 6,7-Diazyl-7-desacetylforskolin.
PH23992A (en) Optically active 2,3-dihydrobenzoxazine derivatives and process for preparing the same
NO854051L (no) Fremgangsm¨te for fremstilling av derivater av tieno- og f uro(2,3-c)-pyrroler.
ATE112264T1 (de) Verfahren zur herstellung von 2,6-di-t-butyl-4- merkaptophenol.
PH18423A (en) Ketoamide derivatives of azetidine sulfonic acid and process for the preparation of azetidine sulfonic acids
DE69009651T2 (de) Verfahren zur Herstellung von 3,4-Dihydrocumarinderivaten.
ES2045861T3 (es) Composicion hipocalorica con cualidades organolepticas analogas a las del huevo entero de gallina y con propiedades nutrientes mejoradas y su procedimieto de preparacion.
KR910002466A (ko) 안정화 fgf 조성물 및 그의 제조방법
ES295383U (es) Mesa desmontable para ordenadores

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 406856

Country of ref document: ES